Pharmacovigilance: A Shared Responsibility for Drug Safety

Pharmacovigilance: A Shared Responsibility for Drug Safety | QbD Group

3:08

Pharmacovigilance (PV) is vital to public health. According to the Spanish Agency for Medicines and Health Products (AEMPS), it ensures that medicines remain safe not only during clinical trials—but even more so after they reach the market.

While Marketing Authorisation Holders (MAHs) are legally responsible for maintaining PV systems, their effectiveness depends heavily on collaboration, especially with healthcare professionals and patients.

These real-world contributors provide key insights into adverse drug reactions that may not appear in tightly controlled clinical trials.

Why Reporting Matters Beyond Clinical Trials

Clinical trials are designed with strict parameters:

short duration
homogenous patient groups
controlled environments

But in real-world use, drugs encounter:

longer treatment periods
diverse populations
complex drug interactions

As a result, new safety information may emerge post-marketing, when medicines are used by larger populations over extended periods.

That’s why spontaneous reporting systems are essential. In Spain, for example, the AEMPS created a public reporting platform to report suspected adverse reactions: 🌐 www.notificaram.es

Who’s Responsible for Pharmacovigilance? More People Than You Think.

To maintain a favorable benefit-risk balance, health authorities and MAHs must continuously collect and assess safety data from a variety of sources. Two of the most important pillars are:

Healthcare Professionals

Physicians, pharmacists, nurses, and other professionals are on the front lines observing, evaluating and reporting suspected adverse reactions. They also contribute through scientific publications that highlight safety concerns, clinical trends, or unusual case reports.

Patients

As daily users of medicines, patients often detect and describe symptoms unexpected ir not described previously. Their voices are crucial for understanding how medicines behave in the real world.

What Happens with the Reported Information?

All reported adverse events are:

evaluated by the MAH
assessed for new safety signals
included in Periodic Safety Update Reports (PSURs).
submitted to regulatory authorities

and used to:

reassess benefit-risk balance
update product information
trigger regulatory actions if needed
in rare cases, withdraw authorisation

This process ensures continuous safety monitoring and long-term patient safety, even years after approval.

How QbD Group Supports Pharmacovigilance Systems

Pharmacovigilance isn’t just a regulatory box to check — it’s a strategic and ethical commitment to public health. At QbD Group, we help our clients build and maintain robust PV systems by providing:

qualified PV staff and local QPPVs
systems for collecting and managing adverse reaction reports
infrastructure for compliant reporting such as dedicated email, hotline, SOPs

Whether you're setting up a new system or need to reinforce an existing one, we’re here to support your pharmacovigilance goals from end to end.

Let’s connect and build safer systems together.

Stay ahead in life sciences

Keeping up with the fast-paced life sciences industry doesn’t have to be overwhelming.

Our newsletter delivers the latest insights, industry updates, and expert content directly to your inbox, helping you stay informed and make smarter decisions.